综述

腺病毒载体在病毒性疫苗中的研究进展

  • 刘晶晶 李玉华
展开
  • null

网络出版日期: 2025-08-16

Progress on adenovirus vector research in viral vaccines

Expand
  • Divisions of Arbovirus Vaccines, National Institutes of Food and Drug Control, Beijing 100050, China

Online published: 2025-08-16

Supported by

null

摘要

基于腺病毒载体安全性好、诱导体液和细胞免疫效率高、容纳外源基因片段大、易于大规模培养等优点,腺病毒载体为构建新型疫苗提供了新的思路与手段。此文简要综述了腺病毒的生物学特性、腺病毒载体的构建策略、以腺病毒为载体构建病毒性疫苗的研究现状和目前存在的问题等,重点介绍了已经进入临床试验阶段的腺病毒载体病毒性疫苗的研究进展。

本文引用格式

刘晶晶 李玉华 . 腺病毒载体在病毒性疫苗中的研究进展[J]. 国际生物制品学杂志, 2017 , 40(5) : 250 -254 . DOI: 10.3760/cma.j.issn.1673-4211.2017.05.010

Abstract

With its good safety, high efficiency in inducing humoral and cellular immune responses, capacity to contain long foreign gene and feasibility of large scale culture, adenovirus vector provides a new means for vaccine development. This paper summarizes the characteristics of adenovirus vector, its construction strategies, current study on adenovirus-vectored viral vaccines and present problems, focusing on development of recombinant adenovirus viral vaccines that have entered into clinical trials.
文章导航

/